Actively Recruiting
Randomized Study of ALTO-300 Compared to Placebo with Open-Label Extension in Adults with Major Depressive Disorder
Led by Alto Neuroscience · Updated on 2026-10-26
325
Participants Needed
75
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy of ALTO-300 compared to placebo as an add-on treatment to antidepressants in adults with moderate to severe major depressive disorder MDD. This Phase 2 study aims to understand how patient characteristics might influence the effectiveness of ALTO-300 in improving depression symptoms. The study uses a randomized, double-blind, placebo-controlled design with a subsequent open-label extension phase. Participants will be assigned to receive either ALTO-300 capsules or matching placebo capsules once daily in the evening for 42 days during the double-blind period. Those who qualify for the open-label phase will continue taking ALTO-300 daily for up to an additional 8 weeks. Throughout both phases, the study monitors treatment effects and safety. During the trial, participants will undergo assessments to measure changes in depression symptoms using the Montgomery-sberg Depression Rating Scale MADRS over six weeks. Safety evaluations include monitoring adverse events, heart rate, weight, blood pressure, and suicidality through specialized questionnaires. The total study duration includes the double-blind phase and the open-label extension, with ongoing safety and efficacy monitoring until study completion.
CONDITIONS
Brief Title
Study of ALTO-300 in MDD
Research Team
A
Alto Neuroscience
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here